
Argenx in US$1.6bn deal with J&J affiliate Janssen
Under the deal, Janssen will pay US$300m in cash to argenx for the global commercialisation rights of cusatuzumab, currently developed in in AML, MDS...

Biomarker predicts response to TNF blockers
The new assay, created by researchers at Sanquin Research in Amsterdam and Pfizer, allowed physicians to measure blood...

New cheap CRS-blockers at the horizon
In mice, the team headed by Bert Vogelstein and Shibin Zhou from Johns-Hopkins University in Baltimore demonstrated that severe...

Adrenomed bags €24m in growth financing
The company said it will use the proceeds to advance clinical testing of adrecizumab, the companies first-in-class antibody targeting endothelial...

Drug dissociates metastasis precursors in blood
In Cell, the team headed by Nicola Aceto from University Hospital Basel, Switzerland, reported that a screening of 2,486 FDA-approved...

Uncommon mutations affect breast cancer prognosis
Patients with oestrogen receptor positive breast cancer often relapse after 5 years of later. To find out more the researchers applied targeted...

Boehringer expands neurology activities
Since 2014, the partners have launched three preclinical research projects in COPD, neuroscience and innate immunity. The new project at BioMed X...